Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of labetalol (a mixed alpha- and beta-adrenergic blocker) and nifedipine (a calcium channel blocker) used primarily for blood pressure control in specific clinical scenarios. This combination leverages the complementary mechanisms of action of both medications to achieve effective blood pressure management, particularly in pregnancy-induced hypertension (PIH) and during electroconvulsive therapy (ECT) in elderly patients. Labetalol is a mixed alpha- and beta-blocker that effectively controls heart rate and blood pressure. It works by blocking both alpha and beta adrenergic receptors, which helps reduce peripheral resistance and cardiac output, leading to decreased blood pressure. Its advantage in pregnancy-related hypertension lies in its ability to control blood pressure without significantly affecting placental blood flow, which is crucial for fetal well-being. Nifedipine is a calcium channel blocker that primarily causes vasodilation, reducing peripheral vascular resistance and subsequently lowering blood pressure. It has additional benefits including increasing prostacyclin levels, preventing platelet aggregation, and promoting fetal lung maturation in pregnant patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on labetalol + nifedipine.